Erste Asset Management GmbH Has $5.13 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Erste Asset Management GmbH reduced its stake in Medpace Holdings, Inc. by 5.5%, owning approximately 0.06% of the company, valued at $5.13 million as of the latest SEC filing.
• Medpace reported earnings of $3.10 per share for the last quarter, exceeding estimates, with revenues of $603.31 million, reflecting a 14.2% year-over-year increase.
• Institutional investors hold 77.98% of Medpace's stock, with recent changes in hedge fund positions suggesting a mixed sentiment among analysts regarding the stock's future performance.

Erste Asset Management GmbH cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,573 shares of the company's stock after selling 973 shares during the quarter. Erste Asset Management GmbH owned approximately 0.06% of Medpace worth $5,128,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Invesco Ltd. increased its stake in shares of Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after acquiring an additional 102,015 shares during the last quarter. Mawer Investment Management Ltd. acquired a new position in Medpace during the first quarter worth $212,131,000. Bessemer Group Inc. increased its position in Medpace by 1.1% during the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock worth $177,411,000 after buying an additional 6,225 shares during the last quarter. AQR Capital Management LLC increased its position in Medpace by 31.3% during the fourth quarter. AQR Capital Management LLC now owns 480,186 shares of the company's stock worth $159,532,000 after buying an additional 114,436 shares during the last quarter. Finally, Northern Trust Corp increased its position in Medpace by 36.0% during the first quarter. Northern Trust Corp now owns 337,489 shares of the company's stock worth $102,830,000 after buying an additional 89,347 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $465.72 on Thursday. The company has a market cap of $13.08 billion, a P/E ratio of 34.63, a P/E/G ratio of 2.91 and a beta of 1.42. The stock's 50-day moving average is $372.56 and its 200-day moving average is $333.62. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the sale, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 112,788 shares of company stock valued at $51,018,354 in the last quarter. Insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MEDP shares. Truist Financial increased their target price on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and increased their target price for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, Mizuho increased their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, Medpace presently has an average rating of "Reduce" and an average price target of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.